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###### The PTK inhibitor, imatinib reverses the damaging effects of DSS treatment in the *Rassf1a^+/−^* but not *Rassf1a^−/−^* knockout mice.

Imatinib was administered intraperitoneally at 60 mg/kg body weight on day 3 and 6 and (A) Disease activity index, (B) cell death using Bax immunoblotting (as an early marker of apoptosis) (in colon lysates), (C) the DNA damage marker phospho-γ-H2AX (in colon lysates) and (D) the oxidative damage marker, HO-1was carried out as indicated (source of sample was colonic mRNA). (E) Purity of our nuclear and cytoplasmic fractions was tested as indicated.

(TIF)

###### 

Click here for additional data file.

###### Further analysis of biomarkers of intestinal inflammation were analyzed.

\(A\) PCNA staining with quantitation on the right panel, (B) Detection of pY-YAP was carried out as indicated, (C) pY-YAP immunohistochemistry carried out, (D) Expression of FLAG-YAP (top panel), GST and GST-1A (bottom panel) used in *in vitro* kinase assay in Fig. 8F.(E) Ubiqutination of p53 was carried out as indicated in colon lysate samples. All baseline (untreated) results not shown were significantly not different from wild type (untreated).

(PDF)

###### 

Click here for additional data file.
